Molecular targeted therapy with transarterial chemoembolization  by Yu, Su Jong & Yoon, Jung-Hwan
lable at ScienceDirect
Gastrointest Interv 2013; 2:78–81Contents lists avaiGastrointestinal Intervention
journal homepage: www.gi - intervent ion.orgReview ArticleMolecular targeted therapy with transarterial chemoembolization
Su Jong Yu,* Jung-Hwan Yoona b s t r a c t
Hepatocellular carcinoma (HCC) remains the third most common cause of cancer-related deaths worldwide, although improvements in patient strati-
ﬁcation and the introduction of novel therapies have improved patient survival. Despite surveillance programs, 80% of HCCs are diagnosed at an advanced
stage, at which point noncurative treatment, including transarterial chemoembolization (TACE) or sorafenib, is indicated. In intermediate stage HCC,
suboptimal treatment outcomes are usually associated with a high rate of recurrence after TACE by eliciting a reaction from vascular endothelial growth
factor. The modest anti-cancer beneﬁts of sorafenib, an anti-angiogenic agent, coupled with its adverse effect proﬁle are two additional barriers to
overcome in treating advanced HCC. Considering the limitations of TACE and sorafenib in intermediate to advanced stage HCC patients, the potential
beneﬁts of combination therapy are attractive. Besides sorafenib, many novel agents are under investigation in Phase III trials of advanced HCC. However,
to date nothing has been shown to perform better than sorafenib. Moreover, recently presented efﬁcacy results evaluating a combination of TACE with
molecularly targeted therapies including sorafenib are less impressive. While TACE or anti-angiogenic therapies results in tumor hypoxia and cell death,
this may also activate hypoxia-induced survival signals including hexokinase II, carbonic anhydrase IX, or protein disulﬁde isomerase. To overcome this
situation, the inhibition of hypoxia-induced survival signals might be additionally required as an adjuvant therapy following TACE or anti-angiogenic
therapies. Therefore, further basic experiments and clinical studies are required to enhance the therapeutic potency of TACE for HCC.
Copyright  2013, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related deaths worldwide and the leading cause of
death in patients with cirrhosis.1,2 HCC is a complex disease that is
dually challenging to treat due to underlying cirrhosis of the liver in
addition to the cancer itself.3 Despite surveillance programs con-
ducted in high-risk populations, most HCCs are diagnosed at an
advanced stage. As a result, only 10–20% of patients are candidates
for curative treatment. The remaining 80% of cases are diagnosed at
intermediate or advanced stages for which noncurative treatment
modalities are recommended. Therapeutically, Barcelona Clinic
Liver Cancer (BCLC) intermediate stage HCC patients are considered
optimal candidates for transarterial chemoembolization (TACE).4
TACE delivers a chemotherapeutic agent into the feeding vessels
of a HCC and produces ischemic insult by blocking subsequent
perfusion of these vessels with a plugging material.5 Two pivotal
randomized controlled trials and a subsequent meta-analysis
conﬁrmed that TACE improved survival in patients with HCC.6–9
However, intermediate stage HCC includes a heterogeneous pop-
ulation of patients that can vary widely in terms of tumor burden,
liver function, and disease etiology.10 A high rate of recurrence and
unsatisfactory treatment outcomes after TACE due to large tumor
size and a high number of tumors remains troublesome.11Department of Internal Medicine and Liver Research Institute, Seoul National University Col
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systemic therapy to demonstrate improved survival in patients
with advanced HCC [10.7 months vs. 7.9 months in the Sorafenib
HCC Assessment Randomized Protocol (SHARP) trial; 6.5 months
vs. 4.2 months in an Asia-Paciﬁc trial].12,13 Given this modest sur-
vival gain and the limitations of sorafenib therapy, such as resis-
tance and tolerability, there are still unmet needs in the treatment
of advanced stage HCC. Currently, multifocal (intermediate BCLC
stage B) HCC is treated primarily with TACE alone and more
advanced (BCLC stage C) HCC is treated with sorafenib mono-
therapy.4 Considering that subsequent recurrence and death is
common in intermediate to advanced stage HCC patients and these
treatments produce a modest survival beneﬁt (median survival
time is about 11–20 months) when used alone,14 the potential
beneﬁts of combination therapy are attractive.10 Recently emerging
molecularly targeted therapies appear to be promising agents in
prolonging the overall survival of late stage HCC patients15 and
these therapies are considered good partners for TACE. However,
anti-angiogenic therapies including TACE cause tumor hypoxia
leading to an upregulation in hypoxia inducible factor-1a (HIF-1a),
which in turn activates hypoxia-induced survival signals that may
promote HCC progression.16 Therefore, understanding and con-
trolling these signals may be essential in maximizing the efﬁcacy of
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using molecularly targeted therapy with TACE and clinical studies
that have investigated these therapies in patients with HCC. Per-
spectives for future developments to improve treatment outcomes
in HCC are also provided.Combination of sorafenib and TACE
Although TACE embolizes themajor feeding arteries of a tumor, it
leaves smaller vessels open, which explains why the procedure is
considered palliative and not curative.5 Moreover, in cases of multi-
focal HCC with a high burden of radiologically invisible foci, these
additional lesions cannot be treated with TACE and TACE may even
promote their growth. TACE induces central anoxia with peripheral
hypoxia. This hypoxic stress provokes cells to release angiogenic
growth factors including vascular endothelial growth factor (VEGF)
andplatelet-derived growth factor (PDGF).17–19 It iswell documented
that circulating levels of VEGF increase after TACE20 and the use of
anti-angiogenic therapy in combination with transarterial emboli-
zation (TAE) is supported in a preclinical model. This combination
causes a reduction in tumor volume and vessel density, as well as a
prolongation in survival compared with TAE alone.21 Therefore, one
improvement in the treatmentofHCCwithTACEwouldbe to prevent
the recruitment of these secondary vessels.
Sorafenib targets and markedly suppresses serine/threonine
kinases of Raf in the MAP kinase cascade, stem cell factor receptor
(c-kit), and inhibits the tyrosine kinases of angiogenesis factor re-
ceptors such as VEGF and PDGF receptors.22 Sorafenib thus simul-
taneously prevents the proliferation of intrahepatic microscopic
remnant tumors after TACE and inhibits angiogenesis.23 In addition,
the ability of sorafenib to induce apoptosis, possibly by inhibiting
the MEK/ERK-independent effects of Raf-1, in a wide variety of
human tumor cell lines, could complement the cytotoxic effects of
standard chemotherapies by re-sensitizing resistant tumor
cells.24,25 Since TACE allows for a combined effect of targeted de-
livery of chemotherapeutic agents with ischemia induced by
embolization,11 sorafenib may augment the efﬁcacy of TACE not
only by inhibiting angiogenesis, but also by enhancing the thera-
peutic efﬁcacy of delivered chemotherapeutic agents through the
induction of apoptosis.
Based on these possible synergistic effects, there are a substan-
tial number of clinical trials assessing the combination of TACEwith
sorafenib that have either been completed or are currently under-
way. The combination of TACE and anti-angiogenic therapy has to
involve careful consideration of the timing of TACE in relation to the
anti-angiogenic therapy.26 That timingmay be critical was shown in
the TACE and sorafenib study published recently by Kudo et al,27
wherein sequential sorafenib therapy demonstrated no added
beneﬁt. Patients with unresectable HCCwere randomized, 229 each
to a sorafenib or placebo group starting 1–3 months after 1–2 ses-
sions of TACE. The median time-to-progression (TTP) in the sor-
afenib group was not signiﬁcantly different from the placebo group
[5.4 versus 3.7 months, respectively; hazard ratio, 0.87; 95% conﬁ-
dence interval (CI), 0.70–1.09; P ¼ 0.252]. The different outcomes
reported by Pawlik et al (a disease control rate of 95% and an
objective response of 58%)28 compared with those of Kudo et al,27
may be due to the timing of sorafenib. In an attempt to explain
the biologic effects of combining anti-angiogenic therapies and
TACE, three models have been proposed: sequential, interrupted,
and continuous.29 The ﬁrst two models address the risk of bleeding
from continuing sorafenib at the time of an invasive vascular pro-
cedure like TACE. The third, a continuous administration approach,
aims at inhibiting the surge of VEGFafter TACE that rises to a peak on
Day 1 and then falls, suggesting that sorafenibmay exert its greatestanti-angiogenic effects when administered before or immediately
after TACE.30 The Phase II randomized, double-blind, placebo-
controlled sorafenib or placebo in combination with TACE in HCC
(SPACE) trial incorporated a continuous sorafenib administration
protocol concurrently with Drug-eluting bead TACE (DEB-TACE).
While the study met its primary endpoint of improving TTP when
sorafenib was added to a regimen of DEB-TACE, the median TTP
reported was similar for both groups (5.6 vs. 5.5 months, respec-
tively).10 The optimal clinical approach will depend on a balance
between safety and efﬁcacy. Positive data from current research
efforts directed at combining molecularly targeted agents with
TACE are needed to recommend this novel therapeutic approach.
Another important clinical concept is whether TACE, as a
powerful complimentary armament to sorafenib, could be allowed
for patientswith advancedHCC. This approach needs to be validated
and the results of an ongoing randomized, controlled Phase III trial
(STAH study) of sorafenib with or without conventional TACE in
patients with advanced HCC (NCT01829035) is eagerly awaited.
Combination of other molecularly targeted therapies and
TACE
Due to genetic heterogeneity, some HCC cells are initially
resistant to sorafenib; this is termed primary resistance.3 Multiple
molecular pathways implicated in the pathogenesis of HCC are now
being evaluated as potential targets for therapeutic interventions,
including VEGF, ﬁbroblast growth factor (FGF), PDGFR, epidermal
growth factor receptor (EGFR), andmammalian target of rapamycin
(mTOR) pathways.22 In addition, there are many other novel agents
and targets in development, including histone deacetylase in-
hibitors (HDAC), c-Met inhibitors, MEK kinase inhibitors, insulin-
like growth factor receptor (IGFR), arginine deiminase, and the
anti-VEGF monoclonal antibody bevacizumab.22 Among these
novel agents, brivanib is a selective dual inhibitor of the FGF and
VEGF receptors that is currently in being investigated in a Phase III
trial (the BRISK-TA study) as adjuvant therapy following TACE in
870 patients with intermediate HCC and compared to placebo
(NCT00908752).22 TSU-68 (orantinib) is an oral, small molecule
inhibitor of VEGFR, PDGFR, and FGFR also currently being evaluated
in a Phase III study (ORIENTAL) in combination with TACE versus
TACE alone (NCT01465464).22 In a pilot study, patients who were
scheduled to undergo TACE were randomized to either observation
(TACE-O) or intravenous bevacizumab (TACE-BEV). The
progression-free survival at 16 weeks was 0.19 in the TACE-O arm
and 0.79 in the TACE-BEV arm (P¼ 0.021). However, the median OS
was similar in both arms [61 months in the TACE-O arm and 49
months in the TACE-BEV arm (P ¼ 0.21)].31
Future perspectives: Experimental agents inhibiting hypoxia-
induced survival signals in HCC
Recently presented efﬁcacy results from multicenter, random-
ized, placebo-controlled clinical trials evaluating a combination of
molecularly targeted therapies, including sorafenib with TACE, are
less impressive in terms of marginal survival beneﬁt. While inhi-
bition of angiogenesis results in tumor hypoxia and cell death, this
may also activate hypoxia-induced cell survival signals, which
might promote HCC progression. Therefore, we brieﬂy summarize
these hypoxia-induced survival signals as novel therapeutic targets
and promising adjuvant therapies for TACE.
Hexokinase II
In hypoxic HCC cells, a glycolytic system induced by hypoxia-
inducible factor-1a (HIF-1a) operates as a salvage pathway to
Gastrointestinal Intervention 2013 2(2), 78–8180produce ATP.32 Hexokinase II (HK-II) is a key enzyme in this system
and might be over-expressed in HCC.33 This enzyme phosphory-
lates glucose, trapping the substrate in the cytoplasm and facili-
tating further glycolysis. We found that hypoxia enhanced HCC cell
growth through HIF-1a-dependent HK-II induction. The HK-II in-
hibitor (3-bromopyrubate, 3-BP) signiﬁcantly inhibited cellular
growth in hypoxic conditions compared to cells in normoxic con-
ditions. This suppression was caused by the induction of HCC cell
apoptosis via activating the mitochondrial apoptotic pathway in
hypoxic cells.34 In another in vitro study, we demonstrated that
hypoxia enhanced mitochondrial stability, which was inhibited by
3-BP treatment.35
In addition, the effect of 3-BP on suppression of tumor growth
was conﬁrmed in an in vivo animal model of HCC. In vivo, the HCC
mouse model was established by intradermal implantation of
MH134 cells in C3H mice. The mean tumor volume and tumor
volume growth were signiﬁcantly reduced in mice treated with 3-
BP. Moreover, the degree of apoptosis quantiﬁed by terminal
deoxyducleotidyl transferase-mediated dUTP nick-end labeling
staining and 99mTc-hydrazinonicotinamide annexin V imaging
was signiﬁcantly reduced after 3-BP treatment.35 These in vitro and
in vivo studies collectively show that hypoxia enhances mito-
chondrial stability through HK-II induction and that treatment with
the HK-II inhibitor 3-BP enhances apoptosis via a mitochondrial
pathway in HCC under hypoxic conditions.
Carbonic anhydrase IX
Glycolysis produces a lot of lactate and carbon dioxide (CO2) as
by-products. The resulting acidic microenvironment causes tran-
sient intracellular acidiﬁcation, which is incompatible with cell
growth and survival. Carbonic anhydrase-IX (CA-IX) is a hypoxia-
inducible transmembrane protein and is involved in lowering pH
by expediting the pericellular metabolism of CO2 in collaboration
with bicarbonate transporters.36 There is a signiﬁcant correlation
between CA-IX expression and the area of hypoxia in solid tumors,
suggesting that this enzyme plays an important role in the adap-
tation of tumor cells in hypoxia.37 Several clinico-pathological
studies indicate that high CA-IX expression in tumors is closely
related to poor prognosis and CA-IX is one of the important survival
mechanisms in cancer cells under acidic environments caused by
hypoxia.38
Our in vitro study conﬁrmed that HCC cells also expressed CA-IX
and that its expression was increased in cells cultured under hyp-
oxic conditions as compared with normoxic cells.39 Even though
CA-IX inhibition alone failed to induce signiﬁcant HCC cell growth
suppression or apoptosis, the inhibition of CA-IX enhanced 3-BP-
induced apoptotic cell death mediated by endoplasmic reticulum
(ER) stress-dependent Jun N-terminal kinase (JNK) activation.39 In
addition, HCC tissues express CA-IX and tumoral CA-IX intensity is
inversely related with E-cadherin intensity, thus potentiating
invasiveness and metastasis.39 Therefore, blocking CA-IX in com-
bination with an HK-II inhibitor might be a useful therapeutic
strategy for hypoxic HCCs.
Protein disulﬁde isomerase
The ER fulﬁlls multiple cellular functions. Because of its role in
protein folding and transport, the ER is also rich in Ca2þ-dependent
molecular chaperones, which stabilize protein-folding in-
termediates. Many disturbances, including glucose deprivation,
misfolded proteins, oxidative stress, and hypoxia can trigger accu-
mulation of unfolded proteins in the ER and lead to ER stress. The
unfolded protein response (UPR) is an important ER stress response
which saves the cell by removing unfolded or misfolded proteins.40In particular, activation of transcriptional induction of ER chaper-
ones, such as protein disulﬁde isomerase (PDI), is involved in
restoring protein folding activity.41 However, excessive and pro-
longed ER stress elicits apoptotic cell death.
It was recently reported that 3-BP, an HK-II inhibitor, may induce
ER stress and thereby cause apoptosis in human HCC cell lines.39
When ER stress is induced by 3-BP, UPR might be activated as a
compensatory mechanism. Thus, we postulated that blocking this
activity may augment ER stress and enhance 3-BP-induced
apoptosis. We adopted bacitracin as a PDI inhibitor to examine the
functional proﬁles of PDI in HCC cells. The peptide antibiotic baci-
tracin was reported to be an inhibitor of PDI in 1981, and since then
has been widely used to demonstrate the role of PDI in cellular
processes.42 Indeed, when bacitracin-treated HCC cells were
treated with 3-BP under hypoxic conditions, apoptosis was signif-
icantly enhanced as compared to cells only treated with 3-BP. We
then found that pro-apoptotic JNKwasmore promptly and potently
activated in cells treated with 3-BP and PDI inhibitor than in cells
only treated with 3-BP. In animal experiments, mean tumor vol-
umes were signiﬁcantly reduced in mice treated with 3-BP and
bacitracin as compared with controls, 3-BP, or bacitracin-treated
mice.43 NONMEM analysis showed that 3-BP and bacitracin had a
synergistic anti-tumor effect. Therefore, a combination of PDI in-
hibitor and HK-II inhibitor may be therapeutically beneﬁcial for
rapidly growing hypoxic HCCs.
Conclusion
The management of HCC has changed substantially in the past
few decades based on recent advances in the understanding of HCC
pathophysiology and the development of new therapies. Based on
new molecular knowledge and recognition of the limitations of
sorafenib, novel molecularly targeted therapies and combination
strategies have been developed. Although early phase data with
these agents have looked promising, to date nothing has been
shown to be better than sorafenib. Incorporating these new agents
as an adjuvant therapy for TACE provides an opportunity to in-
crease our understanding of these agents in HCC. Moreover, inhi-
bition of hypoxia-induced survival signals might be additionally
required as adjuvant therapy following TACE or anti-angiogenic
therapies commonly result in signiﬁcant tumor hypoxia. There-
fore, further basic experiments and clinical studies are required to
enhance the therapeutic potency of TACE in the treatment of HCC.
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